Introduction
The infection, transfection, or transduction of cells, tissues, and organs by necessity involves an interaction of gene transfer vectors or gene medicines with the immune system of the recipient. In the simplest terms, this immune interaction is often viewed as a variant of viral or bacterial pathogenesis. Foreign microbial protein antigens, the components of the vectors, are taken up by professional or nonprofessional antigen-presenting cells (APCs), and the antigens presented in the context of host major histocompatibility complex (MHC) antigens to CD4 + helper T cells. The activated helper T cells then provide additional stimulatory signals to B cells to make antibodies, to induce CD8 + cytotoxic T cells, to activate phagocytic macrophages, or to stimulate other CD4 + T cells.
The resulting inflammatory milieu is then responsible for removing free vector, cell-associated vector, vectortransduced cells, and transgene products. The conceptual framework then for understanding these immune responses, so they can be manipulated and thereby improve the performance of the vectors, has centered around dissecting out how particular vectors interact with classical immune responses. Important components of immunity are the soluble cytokines and chemokines produced by the multifarious interactions among vectors, leukocytes, and parenchymal cells. However, a study of these soluble mediators shows a far more varied and complex series of events than those outlined above, and suggests not only many more levels of immune complexity, but also opportunities to intervene in immune interactions to manipulate vector function.
The section on Adaptive immunity of this review will focus on adaptive immune responses. Immunity is engendered not only in response to specific vector or transgene peptide antigens, but also in response to nonantigenic nucleic acid components, such as CpG motifs. The character of the immune response depends on the type of vector, the route of administration, the parenchymal cell types involved, and the concurrent disease state of the host. Thus, microbial pathogenesis, when viewed from this perspective, is not simply the immune response to foreign viral protein antigens.
The section on Innate immunity of this review will examine chemokines and innate immunity. Recent evidence demonstrates powerful stereotyped responses of leukocytes and tissue parenchymal cells to viruses and nucleic acids. These responses do not depend on classic T-or B-cell immunity. Among these responses are the production of a wide array of potent soluble mediators termed chemokines. Other innate immune responses, which may lead to chemokine production, include the activation of Toll receptors, activation of antigen nonspecific leukocytes, and induction of nucleic acid sensitive intracellular second messenger pathways. Importantly, innate and adaptive immune responses interact, amplify, and regulate each other, which is the focus of the section on Interplay of innate and adaptive immunity of this review.
The section on Cytokine and chemokine regulation of vector function of this review will summarize specific mechanisms of how cytokines and chemokines regulate vector function at the level of individual cells and tissues. Recent reports demonstrate that it is not simply immune clearance of vector, transgene product, or transduced cells that prevents successful gene transfer and expression; but rather more subtle effects on the pathways of vector entry, transport, integration, and transcriptional activation that determine transgene expression. Lastly, the review will draw conclusions about opportunities for further investigation and directions for improving the utility and efficacy of gene medicines.
Adaptive immunity
Adaptive immunity to vector antigens or transgene product can enhance or inhibit the intended therapeutic effect. Antivector immunity can enhance cell killing of target tissue or enhance the effectiveness of immunization for gene therapy for infectious diseases. On the other hand, vector persistence and transgene expression are limited by antivector immunity, a disadvantage in transplantation or metabolic diseases. Adenovirus vectors are the most immunogenic and also the most extensively studied of the gene transfer vectors, from an immunologic perspective; hence most of the discussion that follows refers primarily to adenovirus.
Administration of first-generation, E1/E3-deleted adenovirus vectors generates well-characterized adaptive immune responses against viral capsid proteins.
1,2 The development of cellular and humoral adaptive immunity appears to be the primary mechanism by which transgene expression is extinguished; the cellular arm effecting viral clearance, and the humoral response preventing effective readministration of vector. Each of these immune response is associated with the production of a large number of key cytokines that facilitate T-cell-APC interactions. Transgene expression is generally enhanced when reagents or knockout mice, designed to inhibit adaptive immunity, are utilized. 3, 4 Adeno-associated virus (AAV) vectors, although less efficient than adenovirus vectors, incite much less of an immune response. Consequently, expression by these vectors results in greater vector persistence and transgene expression. 5 Adaptive immunity to adenovirus has been attributed to low levels of viral gene expression, or may reflect contamination by wild-type virus. In support of viral gene expression as a mechanism for antivector immunity is a diminution of Th2 responses and neutralizing antibodies by E4-deleted vectors, 6 and the absence of late inflammation in muscle when 'gutted' vectors lacking all viral genes are employed. 7 However, vectors rendered biologically inactive can generate similar CD4 + and CD8
+ lymphocyte infiltration as do untreated vectors, and antivector CTL responses can be generated in the absence of vector transcription. 8, 9 In addition, empty adenoviral vectors can serve as potent adjuvants, implying that immunogenicity can be independent of vector function. 10 Therefore, cellular responses may not necessarily require viral gene expression. Interestingly, both cellular and humoral immunity can be dramatically diminished by modification of the vector with capsid polyethylene glycol.
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A central component of the immunogenicity of adenovirus vectors appears to be their ability to infect dendritic cells (DCs), the most potent of APC. Adenovirus vectors efficiently infect both mature and immature DCs without altering their maturation or function, as opposed to AAV vectors, which do not transfect DCs. 12 In fact, APCs infected by adenovirus can be adoptively transferred to effect immune-mediated elimination of either adenovirus-or AAV-infected cells. The inability of AAV to transfect or effectively activate APCs may account for their decreased immunogenicity. 13, 14 DCs, which represent potent APCs, play a prominent role in adaptive immune responses to transgenes, via direct vector uptake and gene expression as well as by indirect presentation of soluble antigen. Much of the transgene produced by transfected DC can be presented directly, since depletion of transfected, antigen-bearing DC in draining lymph nodes prevents immunity. 15 In addition, inoculation of plasmid DNA into muscle or skin results in the activation of plasmid-containing DCs at the injection site, in draining lymph nodes, and in systemic circulation. 16, 17 These cells function as APC, can induce specific proliferation of CD4 + T cells and generation of CD8 + CTLs, and can induce both primary and secondary adaptive immune responses. 15, 18 The direct pathway appears to be the primary mode of antigen presentation in this model, rather than indirect presentation of soluble antigen by untransfected DC.
DCs infected in vitro with adenovirus encoding an antigenic peptide can induce specific CTL responses that can be augmented with repeated administration of infected DC. 19 In contrast to direct immunization, which generates neutralizing antibody that may limit repeat administration of vector, low titers of neutralizing antibody are generated with this method. Thus, the capacity of DCs to function as effective APCs may potentially be utilized for therapeutic benefits in designing vaccines or in tumor immunization.
Adaptive immunity to gene therapy vectors is traditionally thought of as being primarily because of vector antigens and transgene product. However, immunity can also be induced by vector nucleic acids. Bacterial DNA is a powerful stimulator of polyclonal proliferation in B cells and cytokine production by monocytes and lymphocytes. 20, 21 These properties are attributed to unmethylated CpG motifs present in plasmid DNA or synthetic oligonucleotides, motifs which are much less frequent in mammalian DNA, which is not immunostimulatory. 22 These responses are sensitive to inhibitors of endosomal acidification, which is coupled to the generation of intracellular reactive oxygen species and the degradation of IkB. 23, 24 Indeed, inhibition of IkB degradation suppresses the immunostimulatory effects of CpG DNA. 25 CpG DNA also induces the activation of c-Jun Nterminal kinase and p38 MAPK, which lead to activation of the transcription factor AP-1. 26, 27 The actions of CpG motifs stimulate the secretion of cytokines such as TNFa and IL-6, monocyte activation, and NK cell activity. 23, 28, 29 The induction of type I interferons, IFNg, IL-12, and IL-18, stimulates Th1 responses and enhance the development of adaptive immunity. [30] [31] [32] [33] Although CpG motifs are generally immunostimulatory to most cell types, evidence exists that different sequences possess different cellular profiles of activity. 22 Efforts to minimize immunostimulation by methylation of CpG sequences are effective in reducing cytokine induction, but impair vector efficiency because of methylation of promoter sequences. 22 
Innate immunity
Gene transfer and vector transduction represent an abortive infection of the target cell. The infection triggers the host immune response, as discussed above, and adaptive immunity plays an important role in vectorinduced inflammation and clearance. However, as the first line of host defense, innate immunity is also stimulated by vector transduction. The innate immune system is a universal and ancient form of host defense mechanism. Compared to the almost limitless diversity of the adaptive immune system, innate immunity is generally considered to be comprised of a limited 34 and soluble components produced by these and other cells (eg, complement, proinflammatory cytokines, and chemokines). These proinflammatory cytokines and chemokines not only play a direct role in clearing pathogens or reducing their spread, but also help shape the downstream adaptive immune responses. 35 Before focusing further on chemokines as the response of the innate immune system to vector transduction, it is important to examine the cellular and molecular elements that result in their induction.
The interaction of a vector with cell surface receptors results in the initiation of multiple signal transduction cascades in the target cells. In particular, many viruses and vectors bind to cell surface receptors, the crosslinking of which subsequently induce NF-kB, 36 ATF-2/cJun, 37 interferon regulatory factors (IRFs), 38 and MAP kinases (p38, ERK, JNK). 39 These pathways ultimately converge in the nucleus to activate a diverse set of immunoregulatory genes, among them the inflammatory cytokines IFNa/b, IFNg, IL-6 and IL-12, [40] [41] [42] and the chemokines RANTES IP-10 and MIP-2. [43] [44] [45] [46] Thus, while innate immunity was previously thought to be a nonspecific immune response characterized by engulfment and digestion of microorganisms, the elucidation of the molecular pathways involved in virus-cell interactions demonstrates that innate immunity also has considerable receptor and ligand specificity.
Toll-like receptors (TLRs) represent another set of specific receptor-ligand interactions, an aspect of the innate immune recognition that has received significant recent attention. The Toll protein was first identified as an essential molecule for embryonic patterning in Drosophila. 47 TLRs are mammalian homologues, expressed at the surface of APCs, which are rapidly activated by pathogen components, such as lipids, carbohydrates, or nucleic acids, that bind to specific TLRs. 48 Distinct TLRs are key molecules in the selective recognition of different pathogens. 49 For example, while not detectable in normal cells, but frequently produced as a result of viral replication, double-stranded RNA (dsRNA) can trigger innate immunity through TLR3. 36 After ligand-mediated dimerization, TLRs recruit an adapter protein MyD88. MyD88 then assembles a signalsome containing IRAK, TRAF6, or ECSIT, [50] [51] [52] and together they mediate activation of NF-kB and MAPKs, and lead to the production of cytokines and chemokines.
dsRNAs enter additional signaling pathways to trigger antiviral responses. dsRNA-dependent protein kinase R (PKR) is activated upon binding to dsRNA. 53 PKR in turn activates NF-kB and the MAP kinase signaling pathway, which leads to IFNa/b induction. 54 dsRNA also activates the 2 0 -5 0 -oligoadenylate synthase (OSA)/ RNaseL pathway. 55 OAS is activated upon binding to viral dsRNA and produces an unusual nucleotide second messenger 2 0 -5 0 oligoadenylate. These oligonucleotides then activate RNaseL, which destroys both viral and cellular RNA. 55 Therefore, in addition to induction of downstream inflammatory genes, dsRNA is able to mediate a direct antiviral mechanism, which includes the cleavage of viral RNA and induction of apoptosis in infected cells because of cleavage of cellular RNA. Indeed, it was reported that PKR and RNaseL suppress gene expression from viral-and nonviral-based vectors, and RNaseL À/À or PKR À/À murine embryonic fibroblasts express enhanced levels of protein from transfected genes compared to wild-type cells. 56 DNA-dependent protein kinase (DNA-PK) is a member of the DNA repair machinery and has a pivotal role in the maintenance of genome stability. 57 Similar to the dsRNA-sensitive enzyme, DNA-PK also plays direct and indirect roles in antiviral responses. It is activated in response to virus infection and phosphorylates IRF-3 on Thr-135, 58 inducing type I IFNs. It has also been reported that DNA-PK inhibits retrovirus integration 59 and that DNA-PK associated with adenovirus E4 gene products inhibits concatamer formation of the adenovirus genome. 60 Since RNaseL and DNA-PK are universally present in all cell types, it is likely that all cells are able to activate inflammatory cytokine production and mount responses to clear vector nucleic acids. The finding that such universal and primitive responses are involved in anti-viral immunity has significantly broadened our definition of innate immunity and should alter future approaches to modify vector structure and delivery to improve vector performance. The various components of innate responses are summarized in Table 1 .
Chemokines induced by vectors
The synthesis of antiviral cytokines and chemokines, not only provides a first line of defense against infection by generating an intracellular environment that restricts virus replication, but also signals the presence of viral pathogens to the adaptive immune system. Work from our laboratory further showed that cytokines and chemokines induced by innate and adaptive antiadenovirus vector immune responses negatively regulate transcription from the vector transgene. 61, 62 Thus, identifying the cytokines and chemokines induced by a particular vector may provide a reasonable strategy to improve the safety and efficacy of these agents for gene medicines.
Chemokines are chemotactic cytokines that signal through G-protein linked, seven transmembrane spanning receptors. Like cytokines, which have pleiotropic effects, chemokines target multiple leukocyte and parenchymal cell subsets. They are essential for the trafficking of DCs and lymphocytes between the sites of infection and lymphoid organs. They enable antigenloaded DCs to home to lymph nodes to prime naïve T and B cells, and generate adaptive immune responses. Chemokines can be divided according to their molecular structure into four subgroups (CXC, CC, C, and CX3C). A functional chemokine classification uses physiological features, which include conditions and locations of chemokine production, as well as cellular distribution of chemokine receptors, to distinguish between 'inflammatory' and 'homeostatic' chemokines. 64, 65 Inflammatory chemokines are specialized in the recruitment of effector cells in response to physiological stress. In contrast, homeostatic chemokines are involved in maintaining physiological trafficking and positioning of cells during hematopoiesis, antigen sampling, and immune surveillance. Since chemokines exert their biologic function through chemokine receptors, their functions can be reflected by the cellular distribution of these receptors. Table 2 shows alternate classifications of chemokines and the cellular distribution of their receptors on immune cells; the classifications are according to chemical structure, biological function, and roles in inflammation.
Most studies investigating vector induction of chemokines have focused on adenovirus vectors, as shown in Table 3 , because of their high transduction efficiency and common usage. Muruve and his coworkers demonstrated that after systemic administration of adenovirus vectors, there is an early dose-dependent inflammatory response associated with a consistent pattern of CXC and CC chemokine induction in murine liver. The neutrophil chemoattractant MIP-2 is first upregulated, followed by predominantly CC chemokines such as MCP-1, RANTES, and MIP-1b, which are mainly monocytemacrophage chemoattractants. The T-cell-specific chemokine most highly expressed following infection with adenovirus vectors was IP-10. 43 Additional studies by the same group showed that the early induction of IP-10 and RANTES was directly mediated through capsiddependent activation of NF-kB, 44, 46 while the activation of p38 MAPK and ERK signaling were involved in the early induction of only IP-10. Recently, using a murine cardiac transplant model and a cDNA array technique, we profiled the chemokine expression patterns in adenovirus vector-transduced or untransduced grafts, and found that adenovirus vector induces a broad panel of inflammatory genes, including the CC chemokines and receptors MCP-1, MIP-1a, MIP1b, RANTES, and CCR5; and the CXC chemokines KC, MIP-2, IP-10, and MIG. Among the potent inflammatory Th1 chemokines such as IP-10 and MIG, their induction by vector occurs earlier and more strongly than after alloantigenic stimulation alone. 66 Similarly, increased expression of MIP-2, MCP-1, and MIP-1b has been demonstrated in the murine respiratory epithelium following intratracheal administration of a first-generation adenoviral vector. 67 AAV vectors are being developed for human gene therapy, because of their long-term gene expression, broad host range, and decreased immunogenicity. 68 A comparison study of the differential activation of the innate immune response by adenovirus versus AAV vectors was recently reported. In vitro, AAV did not induce the same degree of expression of various chemokines in two epithelial-derived cell lines. 69 In vivo, AAV vectors induced only transient chemokine and cytokine expression and leukocyte recruitment in the liver, and this transient induction could be abolished by the depletion of Kupffer cells, suggesting that AAV did not activate the target cells. Thus, the impression that AAV vectors are less immunogenic than adenovirus vectors is supported by this type of analysis of the molecular and cellular components of innate immunity. These approaches demonstrate that it is possible to determine how vectors induce immunity, what precise components of the immune response are induced by individual vectors, how these components influence vector function, and how vectors may be altered or immunity circumvented to improve the performance of gene medicines.
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Interplay of innate and adaptive immunity
The innate and adaptive immune responses are not mutually exclusive processes, with the innate immune response in particular serving to direct and amplify the subsequent adaptive response. Thus, various stimuli such as allergens, infectious agents, or ischemia may each trigger specific components of the innate immune response. In the context of gene transfer, recognition of vector components or viral particles by TLRs or other receptors expressed on macrophages and DCs induces activation of these cells with subsequent upregulation of important costimulatory molecules, such as CD80 and CD86, and class II MHC, thereby maximizing the capacity of these cells to act as professional APCs in adaptive immunity. Vector and viral components also induce proinflammatory cytokines in APC and DC such as IL-1, IL-6, and TNFa, which can further cause local tissue injury, either directly or indirectly because of the production of nitric oxygen or reactive oxygen species intermediates. Tissue injury can result in the further local expression of additional chemokines and chemokine receptors, with recruitment of neutrophils and macrophages and the activation of local endothelium or epithelium. Activation of endothelium and epithelium results in the expression of adhesion molecules and additional chemokines. Activated endothelium can also play a pivotal role in the direct recruitment of antigendependent and -independent inflammatory cells to the site of inflammation. Stimulation of DCs by vector and viral components also induces IL-12, driving T-cell differentiation towards a Th1 phenotype. Macrophages and DCs thus serve as an important link between the innate and adaptive immune responses, by contributing to the recruitment of antigen-specific T cells, and by undergoing enhancement of their capacity to act as professional APCs, most notably for DCs that possess the very strong ability to activate naïve T cells. Once activated, T cells then produce cytokines that act in autocrine and paracrine fashions to amplify the adaptive immune response.
It should be clear from the discussion that interactions between innate and adaptive immunity are not unidirectional, but bidirectional with one response amplifying and affecting the other. It is also clear that much of the communication that occurs among various cell types and between innate and adaptive immunity is mediated by soluble chemokine and cytokine molecules. As is true for most other signaling interactions, there is not a single, well-defined linear pathway, but rather a highly interdependent network with multiple ramifying interactions and a large number of nodes, representing potential points for positive and negative feedback, regulation, and interventional strategies.
Cytokine and chemokine regulation of vector function
Expression by gene transfer vectors is influenced by the type of promoter directing transgene expression. Most common are viral promoters such as MMLV, RSV, SV40, or CMV, but many cellular promoters such as the b-actin promoter are also utilized. Promoter characteristics may have dramatic influences on transgene expression. For example, the efficiency of the CMVie promoter varies depending on whether the promoter is derived from human or murine CMV, on the size of the vector promoter fragment, and on the target cell type. 70 The nature of the promoter may determine interactions with transcription factors and viral gene products that ultimately determine vector efficacy. For example, the RSV but not the CMV promoter can be activated by gene products of the adenoviral E4 region. 71 While the induction of cytokine and chemokines have far reaching effects on antivector immunity, they can also affect vector function more directly. Interactions of promoters with components of the immune system, such as cytokines and chemokines, represent an important means by which transgene expression is attenuated. A variety of cytokines have been demonstrated to inhibit or augment vector promoter function at the transcriptional level. 72, 73 The CMV promoter may be the most widely studied in this regard. While interferons and TNFa are known to have a variety of antiviral activities, such as regulation of MCMV infection and inhibition of reactivation from latency, there is evidence that interferons inhibit the onset of MCMVie gene transcription as well, implying a more direct effect on promoter function. [73] [74] [75] [76] [77] Inhibition of transgene expression by interferons at a post-transcriptional level has been demonstrated in HBV infection, and in MMLV-based retroviral vectors. 78, 79 Promoter attenuation by IL-12 in vivo, mediated by IFNg, has been demonstrated for promoters in nonviral vectors. 80 CMV promoter activity may also increase following adenovirus vector administration, and is stimulated by the transcription factor NF-kB. 81 This may explain the early efficiency of CMV promoter-based vectors, as NF-kB activation can be stimulated by TNFa, IL-1, and IL-6, all of which are induced by vector administration.
Cytokines induced by immune responses to gene transfer vectors may also exert competitive or synergistic effects on transgene expression at the promoter level. We have shown that IFNg and TNFa in combination are synergistic in inhibition of transgene expression by a variety of vectors and promoter types in vitro, and by adenovirus vectors in vivo. 73 In contrast, NF-kB-dependent HIV gene expression is stimulated by TNFa, but inhibited by IFNa by competitive binding of transcription factors induced by these cytokines to the NF-kB coactivator p300. 82 Whether an individual cytokine inhibits or augments transgene expression may also be determined by vector promoter structure; for example, the deletion or mutation of a transcription factor binding site may lead to loss of inhibition by a given cytokine. Characterization of the interactions between cytokines, chemokines, and promoter elements may ultimately lead to the design of gene therapy vectors with promoters that positively interact with the milieu of the target tissue, resulting in augmentation of expression rather than attenuation.
Cytokines, growth factors, and their downstream mediators may also affect vector replication, distribution, and uptake. TNFa, IGF-1, and EGF, which trigger PI3K activation, lead to adenovirus vector internalization, whereas VGEF increases vector entry through effects on microvascular permeability. 83, 84 DNA vectors constructed with repetitive binding sites for NF-kB (which is transported into the nucleus) have dramatically increased uptake compared with unmodified vectors; in addition, these binding sites also function as transcriptional enhancers. 84 In this study, both NF-kB-mediated functions could be regulated by agents that modulate the intracellular distribution of NF-kB, thereby allowing the possibility of regulating vector function by externally modifying the cytokine environment.
Conclusions and future directions
The entry of gene transfer vectors into cells sets into motion two broad categories of immune responses. First, the vectors enter both endocytic vesicles and cytoplasmic spaces and so are potentially available to enter MHC Class II and Class I, respectively, antigen presentation pathways and initiate classical components of microbial immunity. Second, the processes of receptor binding, internalization, uncoating, cytoplasmic entry, nuclear transport, integration, and transcriptional activation are each capable of activating receptors or generating second messengers that influence the expression of many gene products involved in inflammation. Thus, the immune response to vectors is not simply the response to foreign microbial antigens, but is integral to the nature of gene transfer: the act of introducing any vector or nucleic acid into a cell is capable of stimulating adaptive and innate immunity.
The adaptive immune response and the resultant cytokines and chemokines produced will depend on a number of variables. Among the most important are the precise cell types(s) transduced by the vector (professional versus nonprofessional APC), the cell biology of the vector (which antigen presentation pathways it enters), and the nature of other ongoing inflammatory responses because of the disease process for which gene therapy is being administered (infection, cancer, genetic deficiency). Therefore, opportunities for research and development of better vectors and vector performance may lie in preventing vector entry into antigen presentation pathways, in particular, vector entry into professional APC, and modification of costimulatory and coinflammatory signals that accompany specific disease entities. By their very nature, these maneuvers will likely be highly specific for particular vectors, routes of administration, and disease processes. Nonetheless, general principles will probably emerge to deepen our understanding of the barriers that prevent successful gene transfer and also broaden the understanding of microbial pathogenesis.
Similarly, the innate immune response and the cytokines and chemokines produced by innate immunity are integral to the nature of vector entry and transcriptional activation within virtually any cell type, including parenchymal cells, lymphocytes, and professional APC. Research opportunities lie in elucidating the molecular interactions of vector components with cellular receptors and second messenger pathways in cytoplasmic and nuclear domains. These investigations will determine the molecular pathways important for vector gene expression versus those that induce innate immunity. This approach will likely improve vector efficiency, while concomitantly inhibiting innate responses. It is also possible that certain innate responses are inextricably 
